Issue 82

Ceruvia Lifesciences on the mechanism of migraine and prescription psychedelic medicines

Ceruvia Lifesciences focuses on the discovery, development and delivery of psychedelic medicines to address hard-to-treat disorders such as headache disorders, OCD and substance-abuse disorder.

Founded in 2017 by philanthropist Carey Turnbull, Ceruvia Lifesciences was the world’s first producer of cGMP certified LSD and non-hallucinogenic analogue BOL-148, the former which it now provides to researchers for free.

Dr Judy Ashworth, acting Chief Medical Officer, spoke with PSYCH on the company’s creation, its academic research and upcoming clinical trials.

READ MORE
psych capital

PSYCH CAPITAL ANNOUNCES INTENTION TO LIST ON THE AQUIS STOCK EXCHANGE

Psych Capital Plc is a new publicly listed incubation and investment firm, focused on the UK and European psychedelic science and healthcare industry.

Read More

US FEDERAL AGENCY AWARDS US$2.7M GRANT TO DEVELOP PSYCHEDELIC MEDICINES

Funding was given to researchers at the University of California, Davis and the University of Colorado Anschutz Medical Campus.

Read More

BUSINESS AND INVESTMENT

COMPASS releases data from Phase IIb trial.

MindMed releases data from Phase I trials with ibogaine derivative.

Psychedelic medicine for the treatment of mental health issues.

Beckley Psytech partners with Empatica for wearable devices.

Irwin Naturals acquires Ketamine Health Centers.

PharmAla and SABI Mind sign MDMA supply agreement.

SCIENCE AND RESEARCH

The state of psilocybin research.

The potential of psychedelic medicine.

Ketamine in the treatment of alcohol use disorder.

Ketamine in the treatment of depression.

REGULATION AND LEGISLATION

Oregon adopts first legislation for psilocybin framework.

Patents in the development of psychedelic healthcare.

Partner with us